These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1008991)

  • 41. [Present status of hormonal treatment of cancer of the breast and metastasis].
    ROTES-QUEROL J
    Rev Esp Reum Enferm Osteoartic; 1952 Apr; 4(5):325-6. PubMed ID: 13027788
    [No Abstract]   [Full Text] [Related]  

  • 42. The management of advanced breast cancer.
    Hunt PS; Nemoto T
    Med J Aust; 1970 Sep; 2(13):591-4. PubMed ID: 5471114
    [No Abstract]   [Full Text] [Related]  

  • 43. Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel.
    Araki K; Ito Y; Fukada I; Kobayashi K; Miyagawa Y; Imamura M; Kira A; Takatsuka Y; Egawa C; Suwa H; Ohno S; Miyoshi Y
    BMC Cancer; 2018 Oct; 18(1):982. PubMed ID: 30326862
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Peripheral lymphocyte and eosinophil counts as indicators of prognosis in primary breast cancer.
    Ownby HE; Roi LD; Isenberg RR; Brennan MJ
    Cancer; 1983 Jul; 52(1):126-30. PubMed ID: 6850535
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prediction of breast cancer response to endocrine therapy.
    DeSombre ER; Smith S; Block GE; Ferguson DJ; Jensen EV
    Cancer Chemother Rep; 1974; 58(4):513-9. PubMed ID: 4369030
    [No Abstract]   [Full Text] [Related]  

  • 46. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition.
    Kaaks R; Rinaldi S; Key TJ; Berrino F; Peeters PH; Biessy C; Dossus L; Lukanova A; Bingham S; Khaw KT; Allen NE; Bueno-de-Mesquita HB; van Gils CH; Grobbee D; Boeing H; Lahmann PH; Nagel G; Chang-Claude J; Clavel-Chapelon F; Fournier A; Thiébaut A; González CA; Quirós JR; Tormo MJ; Ardanaz E; Amiano P; Krogh V; Palli D; Panico S; Tumino R; Vineis P; Trichopoulou A; Kalapothaki V; Trichopoulos D; Ferrari P; Norat T; Saracci R; Riboli E
    Endocr Relat Cancer; 2005 Dec; 12(4):1071-82. PubMed ID: 16322344
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hormone therapy for cancer. II. Breast and prostate.
    Drug Ther Bull; 1970 Jul; 8(16):61-3. PubMed ID: 5453278
    [No Abstract]   [Full Text] [Related]  

  • 48. The care of terminal and inoperable carcinoma of the breast with emphasis on adrenalectomy, hypophysectomy and hormone therapy.
    WHITTICO JM
    J Natl Med Assoc; 1957 Sep; 49(5):321-6. PubMed ID: 13463593
    [No Abstract]   [Full Text] [Related]  

  • 49. Current status of endocrine therapy for advanced breast cancer.
    Bland KI
    Ann Surg Oncol; 1999 Dec; 6(8 Suppl):4S-7S. PubMed ID: 10619452
    [No Abstract]   [Full Text] [Related]  

  • 50. [Hormone therapy in metastasizing breast carcinoma].
    Hülshoff T
    Z Allgemeinmed; 1971 Oct; 47(28):1456-9. PubMed ID: 5116910
    [No Abstract]   [Full Text] [Related]  

  • 51. Enumeration of lymphocytes and their subpopulations identified by bacterial adherence in blood smears of patients with breast tumors.
    Felix E; Katz S; Teodorescu A; Teodorescu M
    J Surg Oncol; 1981; 18(4):323-9. PubMed ID: 6976487
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Hormone therapy of breast and prostate carcinoma].
    OBRECHT P
    Dtsch Med Wochenschr; 1957 Dec; 82(50):2117-21. PubMed ID: 13500952
    [No Abstract]   [Full Text] [Related]  

  • 53. [Hormone-therapy of carcinoma of the breast].
    Villani C; Mazzon I
    Minerva Ginecol; 1981 Jan; 33(1):3-26. PubMed ID: 7017505
    [No Abstract]   [Full Text] [Related]  

  • 54. Thymus and breast cancer--plasma androgens, thymic pathology, and peripheral lymphocytes in myasthenia gravis.
    Papatestas AE; Mulvihill M; Genkins G; Kornfeld P; Aufses AH; Wang DY; Bulbrook RD
    J Natl Cancer Inst; 1977 Dec; 59(6):1583-8. PubMed ID: 144802
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predictive value of lymphocyte-to-monocyte ratio in the preoperative setting for progression of patients with breast cancer.
    Goto W; Kashiwagi S; Asano Y; Takada K; Takahashi K; Hatano T; Takashima T; Tomita S; Motomura H; Hirakawa K; Ohira M
    BMC Cancer; 2018 Nov; 18(1):1137. PubMed ID: 30453914
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Current perspectives in the treatment of breast cancer.
    Freed N
    J Am Osteopath Assoc; 1979 Feb; 78(6):420-5. PubMed ID: 422404
    [No Abstract]   [Full Text] [Related]  

  • 57. [Endocrine therapy of the metastasizing carcinoma of the breast].
    WALSER A
    Schweiz Med Wochenschr; 1956 May; 86(20):497-501. PubMed ID: 13337273
    [No Abstract]   [Full Text] [Related]  

  • 58. [Problem of therapy with sex hormones in aging women].
    Nowakowski H
    Zentralbl Gynakol; 1966 Sep; 88(39):1302-3. PubMed ID: 5989665
    [No Abstract]   [Full Text] [Related]  

  • 59. Phase I study of phenesterin (NSC-104469).
    Ansfield FJ; Carter AC; Goldenberg IS; Segaloff A
    Cancer Chemother Rep; 1971 Jun; 55(3):259-63. PubMed ID: 5000532
    [No Abstract]   [Full Text] [Related]  

  • 60. Aminoglutethimide induced hormone suppression and response to therapy in advanced postmenopausal breast cancer.
    Harris AL; Dowsett M; Smith IE; Jeffcoate S
    Br J Cancer; 1983 Oct; 48(4):585-94. PubMed ID: 6684948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.